Decision path
Use the guide as a safety framework.
Learn the framework first, then check risk, vendor documentation, and personal fit before choosing a compound path.
01
Learn the framework
02
Check risk
03
Take the quiz
04
Compare vendors
Guide next step
Use the guide before choosing a compound.
Take the quiz after this guide so the next page reflects your goal, risk tolerance, and monitoring comfort.
Why this matters
Safety discussions in this space are often too casual or too vague.
A product can have an interesting mechanism and still be a bad research choice for most users.
The site needs a consistent way to talk about risk without collapsing into hype or fearmongering.
Key takeaways
Evidence quality and safety are related, but not identical. Strong evidence can still come with meaningful side effects, and weak evidence often means larger unknowns.
Route matters. Injectable, oral, topical, and blended products raise different questions.
Product quality is part of safety. Poor documentation and weak lot traceability are risk signals.
You should always separate biological risk, compliance risk, and sourcing risk.
Guide protocol path
Use this framework before turning research into a protocol.
- 1
Baseline
Clarify goal, labs, contraindications, and sport/testing status.
- 2
Choose
Pick one primary compound path before stacking extras.
- 3
Source
Check vendor documentation, COA fit, and route constraints.
- 4
Monitor
Track outcomes, adverse effects, and stop conditions.
- 5
Reassess
Review whether the protocol still fits after the first cycle.
COA visual
How to read a COA before trusting a vendor
Example certificate
Product purity and identity report
Batch ID
Must match the exact product page or vial label.
Purity
Look for a numeric purity result, not only 'lab tested' language.
Method
HPLC is common for purity; MS helps confirm identity.
Date
Recent tests are more useful than stale or reused reports.
Red flags
Missing batch, cropped lab name, or generic PDF should slow the purchase.
Think in three kinds of risk
The most common traps
If the documentation is weak, the risk is higher
A vendor-quality problem is not separate from safety. It is part of the safety conversation because it changes what the user can trust about the product itself.
Frequently asked questions
Because they answer different questions. Evidence tier asks how well studied something is. Risk level asks how cautious the user should be with the compound and context.
Yes. Fit still matters. A lower-risk option can still be the wrong match for your goal, your standards for evidence, or the kind of product you are trying to research.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Use these guides to build confidence first — then compare compounds, review vendor documentation, and take the quiz when you're ready for a plan.